Admiraal P J, Derkx F H, Danser A H, Pieterman H, Schalekamp M A
Department of Internal Medicine, University Hospital Dijkzigt, Rotterdam, The Netherlands.
Hypertension. 1990 Jan;15(1):44-55. doi: 10.1161/01.hyp.15.1.44.
To study the metabolism and production of angiotensin I, highly purified monoiodinated [125I] angiotensin I was given by constant systemic intravenous infusion, either alone (n = 7) or combined with unlabeled angiotensin I (n = 5), to subjects with essential hypertension who were treated with the angiotensin converting enzyme inhibitor captopril (50 mg b.i.d.). Blood samples were taken from the aorta and the renal, antecubital, femoral, and hepatic veins. [125I]Angiotensin I and angiotensin I were extracted from plasma, separated by high-performance liquid chromatography, and quantitated by gamma counting and radioimmunoassay. Plasma renin activity was measured at pH 7.4. The plasma decay curves after discontinuation of the infusions of [125I]angiotensin I and unlabeled angiotensin I were similar for the two peptides. The regional extraction ratio of [125I]angiotensin I was 47 +/- 4% (mean +/- SEM) across the forearm, 59 +/- 3% across the leg, 81 +/- 1% across the kidneys, and 96 +/- 1% across the hepatomesenteric vascular bed. These results were not different from those obtained for infused unlabeled angiotensin I. Despite the rapid removal of arterially delivered angiotensin I, no difference was found between the venous and arterial levels of endogenous angiotensin I across the various vascular beds, with the exception of the liver where angiotensin I in the vein was 50% lower than in the aorta. Thus, 50-90% of endogenous angiotensin I in the veins appeared to be derived from regional de novo production. The blood transit time is 0.1-0.2 minute in the limbs and in the kidneys and 0.3-0.5 minute in the hepatomesenteric vascular bed. This is too short for plasma renin activity to account for the measured de novo angiotensin I production. It was calculated that less than 20-30% in the limbs and in the kidneys and approximately 60% in the hepatomesenteric region of de novo-produced angiotensin I could be accounted for by circulating renin. These results indicate that a high percentage of plasma angiotensin I may be produced locally (i.e., not in circulating plasma).
为研究血管紧张素I的代谢和生成,对接受血管紧张素转换酶抑制剂卡托普利(50毫克,每日两次)治疗的原发性高血压患者,通过持续全身静脉输注给予高度纯化的单碘化[125I]血管紧张素I,单独输注(n = 7)或与未标记的血管紧张素I联合输注(n = 5)。从主动脉以及肾静脉、肘前静脉、股静脉和肝静脉采集血样。从血浆中提取[125I]血管紧张素I和血管紧张素I,通过高效液相色谱法分离,并用γ计数和放射免疫测定法定量。在pH 7.4条件下测量血浆肾素活性。停止输注[125I]血管紧张素I和未标记的血管紧张素I后,两种肽的血浆衰变曲线相似。[125I]血管紧张素I在前臂的区域提取率为47±4%(平均值±标准误),在腿部为59±3%,在肾脏为81±1%,在肝肠系膜血管床为96±1%。这些结果与输注未标记血管紧张素I所获得的结果无差异。尽管动脉输送的血管紧张素I被迅速清除,但除肝脏外,在各个血管床中内源性血管紧张素I的静脉血和动脉血水平之间未发现差异,肝脏静脉中的血管紧张素I比主动脉中的低50%。因此,静脉中50 - 90%的内源性血管紧张素I似乎源自局部从头生成。肢体和肾脏中的血液通过时间为0.1 - 0.2分钟,肝肠系膜血管床中的为0.3 - 0.5分钟。这对于血浆肾素活性来说太短,无法解释所测量的从头生成的血管紧张素I的量。据计算,肢体和肾脏中从头生成的血管紧张素I中不足20 - 30%以及肝肠系膜区域中约60%可由循环肾素解释。这些结果表明,血浆血管紧张素I的很大一部分可能是在局部产生的(即不是在循环血浆中)。